Company intelligence / Profile preview

Abomics

Turku, Southwest Finland / Varsinais-Suomi region, Finlandabomics.fi ↗

Ownership: Private
Development stage: Commercial

Overview

Abomics specializes in providing pharmacogenetic testing services and interpretation tools that help clinicians personalize drug therapy based on genetic information. Their databases integrate with electronic health records to support evidence-based prescribing. The company’s solutions are widely adopted in Finland and expanding internationally. Clinical results show a reduction of adverse drug reactions by up to 30% when using their reports for medication decisions.

Therapeutic areas: PsychiatryCardiovascularNeurology
Industry: Molecular Diagnostics

Partnerships

Duodecim Medical Publications Ltdvarious healthcare providers/laboratories across Europe

Beyond the preview

Go deeper on Abomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abomics.

Explore the full profile